AZN vs BBIO

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

The company exhibits extremely weak fundamental health with a Piotroski F-Score of just 1/9, indicating severe financial distress. Despite explosive revenue growth of 4318% YoY and strong analyst recommendation of 'strong_buy', profitability remains deeply negative with operating and net margins at -112.97% and -225.32% respectively. Insider selling is aggressively bearish, with $56.6M in sales over the last six months and zero buys, contradicting the bullish analyst stance. While liquidity ratios are healthy (Current Ratio: 3.88), the lack of Altman Z-Score and negative valuation metrics suggest high risk and speculative pricing not supported by earnings or cash flow.